Astaxanthin

PBIO Receives Critical Processor License for Industrial Hemp in MA.New License and Relocation to Enhanced Manufacturing Facility Allows Company to Supplement Production with West Coast Partner to Manage Anticipated Onset of Purchase Order Increases. CANTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today announced that its wholly-owned Uncle Bud’s Health & Wellness consumer packaged goods subsidiary (“Uncle Bud’s”) has experienced significant sales activity in its revolutionary nanoemulsified CBD product offered in the initial launch of its highly touted “Premium Collection” of UltraShear™ processed nanoemulsion products. Click here for more info on Uncle Bud's Premium Collection. In an exciting move for natural wellness enthusiasts, Uncle Bud’s recently launched its UltraShear-processed “Premium Collection” of state-of-the-art nanoemulsified products, representing the pinnacle of innovation, quality, and commitment to clean and all-natural wellness solutions. The Premium Collection was an immediate success, highlighted by the unprecedented response to its initial product in the Collection - the CBD Body Revive Spray with 1200mg of Nano-CBD. PBIO’s multi-patented Ultra Shear Technology™ (UltraShear™ or UST™) platform allows oil-soluble active molecules (e.g., vitamin D3, retinol, CBD) to be prepared into high quality nanoemulsions that ensure rapid absorption and unparalleled bioavailability of the oil-based active ingredients into the water-based biochemistry of humans, animals, and plants. A recently published scientific study in a peer-reviewed journal by world-renowned researchers confirmed PBIO’s UltraShear nanoemulsion platform vastly outperformed other delivery systems with unmatched speed, efficiency, and bioavailability. UltraShear Bioavailability Study 2023. “Uncle Bud’s newly launched Nano-CBD Body Revive Spray, an innovative, all plant-based, organic, highly bioavailable flagship product processed using PBIO’s UltraShear platform, captured an impressive 30% conversion of Uncle Bud’s total CBD Revive Spray product revenue in March alone,” commented John Hollister, PBIO’s Director of Sales and Marketing. “The surge in demand for this revolutionary new product prompted an urgent restocking of this initial product in Uncle Bud’s Premium Collection, in order to meet the enthusiastic consumer response to date!” In a separate, critically important accomplishment, PBIO announced it had received its Massachusetts processing license for industrial hemp (No. 25240244P). The license was granted by the MA Department of Agricultural Resources (“MDAR”), the hemp processing licensing entity under federal and state law in the Commonwealth of MA. This achievement enables PBIO to develop, manufacture, market, and sell UST-processed products into the rapidly expanding CBD marketplace. Ken Micciche, PBIO’s Director of Business Development, added: “With our relocation into a larger and significantly enhanced manufacturing facility, with our new MDAR processor license, and with an accelerated focus on the generation of major revenue from sales of our unique nanoemulsified products, we are now prepared for the expected onset of orders for existing (e.g., CBD, Astaxanthin) and new (e.g., Acai, Retinol) UltraShear-processed nanoemulsified products.” About Uncle Bud’s Health and WellnessLaunched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud’s has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud’s brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud’s is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations – including the revolutionary performance breakthroughs delivered by PBIO’s patented UltraShear™ processing platform. Uncle Bud’s diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow Us On Social Media: @UncleBuds_Hemp. About Pressure BioSciences, Inc.Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our patented, scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform allows for the creation of stable nanoemulsions of otherwise immiscible oil-based active components in water. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our patented original enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. Our patented BaroFold™ technology platform positions us to provide valuable contract services and GMP manufacturing equipment to the bio-pharmaceuticals industry. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers. Forward Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. For more information about PBIO, Uncle Bud’s, and this press release, please click on the following website links:http://www.pressurebiosciences.com www.unclebudshemp.com Please visit us on Facebook, LinkedIn, and Twitter. CBD Body Revive SprayAll Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class,UltraShear-processed Nano CBD…the first in a series of groundbreaking premium nanoemulsified products designed to meet the needs of consumers looking for the highest quality and performance in natural and effective wellness solutions.Click here for more info on Uncle Bud's Premium Collection. Press Contacts: Richard T. Schumacher, President & CEOJohn B. Hollister, Director of Sales and MarketingKenneth F. Micciche, Director of Business Development (508) 230-1828 (T)(805) 908-5719 (T)(508) 230-1828 (T) A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a5bec8b-25e8-44cb-83de-1368fd142375

Company's innovative approach enables high-quality natural algae astaxanthin production at faster and more affordable rates New funding will support company plans to reach commercialization this year HONOLULU, March 13, 2024 /PRNewswire/ -- Kuehnle AgroSystems ("KAS"), a leading microalgal innovation and production company, today announced that it has raised a $3 million Series A2 funding round led by S2G Ventures. The funding will accelerate the commercialization of KAS's pioneering method for producing natural astaxanthin from microalgae, a key component in sustainable aquaculture systems as well as a clinically proven human nutraceutical. KAS has patented an innovative process that uses dark fermentation in closed vertical tank systems to produce high-quality natural algae astaxanthin. Utilizing a more sustainable feedstock and production method than current natural and synthetic astaxanthin production methods, KAS's process results in lower production costs, higher yields, faster growth times, and less water and energy consumption. Astaxanthin is a carotenoid with antioxidant properties present in natural aquatic algae, which is consumed by salmonids and shrimp and gives these species their characteristic red color. In aquaculture systems, which produce over 50% of the seafood we eat globally, astaxanthin is incorporated to provide similar pigments. However, 95% of astaxanthin currently used in aquaculture feed is synthetic and derived from petrochemicals. KAS aims to replace synthetic with natural algal astaxanthin, addressing a market that is estimated to be valued at around $3.7 billion. "Strong consumer preference for natural inputs is expected to accelerate the transition from synthetic to natural astaxanthin," said Claude Kaplan, chief executive officer of KAS. "With our ability to generate greater astaxanthin output volumes, quicker and at a reduced cost compared to light-dependent methods, this funding strongly positions KAS to respond to the rapidly expanding needs of the market." "KAS's fermentation breakthrough, natural strain development process, and sustainable production method all have the potential to transform the natural astaxanthin market, a key input for more sustainable aquaculture practices that can drive better outcomes for people and the planet," said Larsen Mettler, Managing Director at S2G Ventures. "We are proud to be part of KAS's journey and look forward to supporting the impact they are poised to make in the market." Existing backers of KAS include Aqua-Spark, Hatch and Cavallo Ventures. "We continue to be impressed by the KAS team's capacity to leverage their scientific and commercial knowledge to produce a truly innovative solution for replacing synthetic with natural astaxanthin," said Lissy Smit, CEO at Aqua-Spark. "As the aquaculture industry continues to grow at a rapid pace, we need more companies like KAS that are solving core challenges in the value chain to ensure our food system is healthier and more sustainable for consumers and the planet." KAS will initially launch with its European-based production partner with the capacity to distribute globally. This new funding will enable KAS to exploit its ability to use standard fermentation equipment, to swiftly expand production through leveraging contract manufacturers, with the option to bring production in-house in the future. And while KAS' process is inherently more resource efficient than competitors, the company's technology also holds future potential for recycling the gas generated during fermentation to produce feedstock to be fed back into the fermentation process creating fully circular algal products. About KAS: Kuehnle AgroSystems, Inc. (KAS), founded in 2007, is a Hawaii-based microalgae development company with a world-class team of professionals. KAS uses its extensive library of Hawaiian microalgal strains to research, develop and produce specialty chemicals and raw materials to make life better. Our customers include multinational corporations along with valued regional companies and brands that require sustainable plant-based ingredients for animal feeds, human health, food, and personal care. Industrial fermentation allows our ingredients to be cultured at lower cost with highest efficiency and quality, and enables rapid access to markets by ourselves and our partners. Learn more at kuehnleagro.com. About S2G Ventures: S2G Ventures partners with entrepreneurs who are working on solutions to some of the world's greatest challenges across the food, agriculture, oceans, and energy markets. The firm provides capital, mentorship, and value-added resources to companies pursuing innovative market-based solutions that generate positive social, environmental, and financial returns. S2G structures flexible capital solutions that can range from seed and venture funding through growth equity to debt and infrastructure financing. For more information about S2G, visit s2gventures.com or connect with us on LinkedIn. Media Contact: Chelsea Hokenson [email protected] SOURCE Kuehnle AgroSystems